NeuroKine Therapeutics LLC (NKT) is a clinical stage drug development company structured around selective serine/threonine protein kinase (ST PK) inhibitors with safe and effective pharmacological properties for neurologic indications. Deliverables are new chemical entities with potential for disease modification in areas of unmet medical need such as Alzheimers Disease, tauopathies and other CNS disorders. ST PKs are critical intracellular regulators and integrators of homeostasis. Clinical and preclinical evidence implicates ST PKs, such as stress related kinases, as potential neurotherapeutic targets. NKT uses a platform that can deliver significantly de-risked CNS PK inhibitor drug candidates. The pipeline includes a first-in-class, potential disease modifying, therapeutic candidate at clinical trial stage.
